Incentivizing Antibiotic Research and Development

Abstract

; and most significantly Professor Albert Wertheimer, PhD, who had a seemingly endless store of inspiration and encouragement.In some parts of this manuscript, we include screenshots of information publicly available on the Internet. We include these under fair use guidelines in which we reproduce them for purposes such as criticism, comment, reporting, teaching, scholarship and research. Abstract This paper explores the current situation regarding antibiotic resistance and its casualties, as well as the mechanisms being employed to overcome the increase in resistance, and decrease in antibiotic effectiveness. Through analysis of antibiotic research, development, and regulation, this paper adds to the discussion by filling in the current gaps regarding the procurement of sustainable funding via an insurance model framework. By incentivizing the pharmaceutical industry to invest in antibiotic research, and by guaranteeing returns on investment, a global solution to the current antibiotic resistance problem can be contained. IntroductionWe are on the dawn of an international crisis. Infections are getting harder to treat, treatments are becoming more frequent, more expensive, and more people are dying.1,2 Multi-drug resistant organisms (MDRO) are being found all over the world. 3 Many fear

The value of innovation under value-based pricing

“…In this sense, drugs aimed at treating diseases with a growing incidence rate, like antibiotics for antimicrobial resistance, are granted significantly higher prices compared to the conventional VBP approach. This supports the belief that the conventional VBP approach is falling short when valuing such technologies because it disregards the benefit to future patients ( 35 – 37 ). This undervaluation is a direct consequence of applying a static perspective when making allocation decisions (that maximize the surplus of prevalent patients given existent NHS resources).…”